Abstract

Objective To investigate the effects of artificial CO2 pneumoperitoneum on hypoxia inducible factor-1α ( HIF-1α) , vascular endothelial growth factor (VEGF) , E-cadherin expression of renal cell carcinoma cells, and to explore its regulatory mechanisms. Methods Human renal clear cell carcinoma cells (RCC-949) were cultured in artificial CO2 pneumoperitoneum at 21℃, 99% CO2, 1% O2, 15 mm Hg ( 1 mm Hg = 0. 133 kPa) for 1, 2, 4 h, and the mRNA and protein expression of HIF℃ and VEGF and E-cadherin was detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively. RCC-949 cells cultured in culture fluid containing 10μmol/L chloride cobalt (CoCl2 ) served as positive hypoxia controls. Correlation analyses were performed to investigate their regulatory relationship. Results After culture in artificial CO2 pneumoperitoneum for 1, 2, 4 h, as compared with the control group, HIF-1α protein and mRNA expression levels of RCC-949 cells were increased by 37% , 68% , 158% and 1371% , 1784% , 2374% , and VEGF protein and mRNA expression levels increased by 77% , 103%, 172% and 1582%, 2107% , 2432% , but E-cadherin protein and mRNA expression levels decreased by 17% , 27%, 44% and 43% , 71%, 95% respectively, and there were significant differences ( P 〈 0.05 ). Correlation analysis showed that there was a positive correlation in mRNA (0. 918,P 〈 0.01 ) and protein expression (0. 856, P 〈 0. 01 ) between HIF-1α and VEGF, while there was a negative correlation in mRNA ( - 0. 709, P 〈 0. 05 ) and protein expression ( - 0. 667, P 〈 0. 05 ) between HIF-1α and E-cadherin. Conclusion The effects of CO2 pneumoperitoneum on HIF-1α, VEGF and E-cadherin expression of renal cell carcinoma cells might be mediated by hypoxia, and HIF-1α might be the initiation factor of regulatory network of RCC-949 tumorigenicity in artificial CO2 pneumoperitoneum. Key words: Renal cell carcinoma; Pneumoperitoneum ; Hypoxia inductive factor-1α; Vascular endothelial growth factor; E-cadherin

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.